Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT04017455
PHASE2
Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)
Sponsor: The Netherlands Cancer Institute
View on ClinicalTrials.gov
Summary
In this study, patients with resectable rectal cancer will receive radiotherapy, followed by neoadjuvant bevacizumab and atezolizumab
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
38
Start Date
2019-10-22
Completion Date
2025-08-31
Last Updated
2025-06-08
Healthy Volunteers
No
Conditions
Interventions
DRUG
Atezolizumab
3 cycles of atezolizumab 840 mg
DRUG
Bevacizumab
3 cycles of bevacizumab 5mg/kg
Locations (1)
Marieke van de Belt
Amsterdam, North Holland, Netherlands